BHX, a novel pyrazoline derivative, inhibits breast cancer cell invasion by reversing the epithelial-mesenchymal transition and down-regulating Wnt/β-catenin signalling

Abstract

The novel pyrazoline derivative, BHX, has recently been shown to exhibit potent anti-tumour activity by blocking the Wnt/β-catenin signalling pathway. However, its effect on breast cancer growth and invasion are unknown. Our results show that BHX suppresses MDA-MB-231 cell viability and colony formation in a dose-dependent manner, and induces apoptosis and G0/G1 phase arrest. BHX-treated breast cancer cells showed morphological characteristics of cells undergoing apoptosis. Furthermore, BHX inhibited cell migration and invasion, which was associated with increased E-cadherin mRNA and protein expression, and down-regulation of SNAIL and vimentin. In addition, BHX induced the generation of intracellular ROS and decreased β-catenin protein and mRNA expression. We used a mouse xenograft model to investigate the effects of BHX in vivo, where the growth of MDA-MB-231 xenografted tumours was suppressed in nude mice treated continuously with BHX for 21 days. Finally, the rat plasma concentration of BHX was measured by ultra-performance liquid-chromatography tandem mass spectrometry and the pharmacokinetic parameters of BHX were processed by non-compartmental analysis. In conclusion, BHX merits further study as a novel therapeutic small molecule for the treatment of breast cancer.

MicroRNA‑192 acts as a tumor suppressor in colon cancer and simvastatin activates miR‑192 to inhibit cancer cell growth

“…As a marker of interstitial cells, the elevated expression level of β-catenin indicates the transformation of epithelial cells into mesenchymal cells. In contrast, the reduced level of β-catenin expression is a sign that the EMT process is suppressed (20)(21)(22). In the present study, the effect of simvastatin on the mRNA levels of downstream pathway proteins was investigated.…”

Apoptosis: A Target for Anticancer Therapy

“…Targeting apoptosis is also effective for all types of cancer, as apoptosis evasion is a hallmark of cancer and is nonspecific to the cause or type of the cancer. There are many anticancer drugs that target various stages in both the intrinsic and extrinsic pathways [ 7 , 8 , 9 ]. Two common strategies for therapeutic targeting are stimulation of proapoptotic molecules and inhibition of antiapoptotic molecules [ 2 ].…”

The Role of Galectins in Cervical Cancer Biology and Progression

“…Since apoptosis avoidance is a characteristic of cancer, targeted apoptosis may become the most successful nonsurgical treatment. Nowadays, many antitumor drugs are aimed at different endogenous and exogenous pathways [ 48 – 50 ]. Two commonly used therapeutic targeting strategies are stimulating apoptotic molecules and inhibiting antiapoptotic molecules [ 51 ].…”